Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
Clinical complete response of 43 percent seen for those with muscle-invasive bladder cancer receiving neoadjuvant gemcitabine, cisplatin, plus nivolumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.